Inactive Instrument

Telcon Inc Stock Korea S.E.

Equities

Communications & Networking

Financials

Sales 2022 27.83B 20.09M 0 27.44M Sales 2023 36.31B 26.21M 0 35.8M Capitalization 97.67B 70.52M 0 96.31M
Net income 2022 -42.08B -30.38M - -41.49M Net income 2023 13.91B 10.04M - 13.71M EV / Sales 2022 4.7 x
Net Debt 2022 20.54B 14.83M 0 20.25M Net Debt 2023 16.9B 12.2M 0 16.67M EV / Sales 2023 3.16 x
P/E ratio 2022
-2.56 x
P/E ratio 2023
8.52 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 75.55%
More Fundamentals * Assessed data
TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 22 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd. CI
Abion Inc. announced that it has received KRW 19 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank CI
TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 22 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd. CI
Abion Inc. announced that it expects to receive KRW 19 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank CI
Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc. CI
TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 6 billion in funding from Abion Inc. CI
TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 6 billion in funding from Abion Inc. CI
Abion Inc. announced that it expects to receive KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc. CI
TELCON RF PHARMACEUTICAL. Inc.(KOSDAQ:A200230) dropped from S&P Global BMI Index CI
TELCON RF PHARMACEUTICAL. Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
TELCON RF PHARMACEUTICAL. Inc. Auditor Raises 'Going Concern' Doubt CI
KPM TECH Co., Ltd. announced that it has received KRW 9.99999925 billion in funding from TELCON RF PHARMACEUTICAL. Inc. CI
KPM TECH Co., Ltd. announced that it expects to receive KRW 9.99999925 billion in funding from TELCON RF PHARMACEUTICAL. Inc. CI
Humanigen’s Partner in South Korea Receives Ministry of Food and Drug Safety Approval to Conduct Phase 1 Study of Lenzilumab CI
Humanigen, Inc Announces the Execution of Licensing Agreement with Telcon Rf Pharmaceutical, Inc. and KPM Tech Co., Ltd CI
More news
Managers TitleAgeSince
Chief Executive Officer 54 18-06-07
Director of Finance/CFO 48 19-03-27
Chief Tech/Sci/R&D Officer 46 00-04-30
Members of the board TitleAgeSince
Director/Board Member 54 16-07-13
Director of Finance/CFO 48 19-03-27
Director/Board Member 47 19-03-27
More insiders
TELCON RF PHARMACEUTICAL. Inc., formerly TELCON.Inc, is a Korea-based company principally engaged in the manufacture and distribution of connectors and cable assemblies. The Company’s products mainly consist of radio frequency (RF) connectors, RF cables, couplers, dividers, arrestors, terminations, adapters, and other cable assemblies, which are used for wireless communication equipment.
More about the company